1 completed, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow nulibry: new trials by email Literature Review of nulibry trials Research Report on nulibry
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers ALXN1101, Placebo - Molybdenum Cofactor Deficiency (MoCD), Rare Autosomal Recessive Disorder | Phase 1 | Completed | Origin Biosciences | 24 | 2013-06-01 | 2019-03-19 |
| Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A cPMP - Molybdenum Cofactor Deficiency Type A | Phase 1 / Phase 2 | Withdrawn | Orphatech Pharmaceuticals, GmbH | 10 | 2009-08-01 | 2011-02-01 |
Molybdenum Cofactor Deficiency, Complementation Group A (1) · Molybdenum cofactor deficiency (1)
Origin Biosciences (1) · Orphatech Pharmaceuticals, GmbH (1)
Australia (1) · United States (1)
Alex Veldman, MD (1) · Ronald Goldwater, MD (1)